EXHIBIT A 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 1 of 43
[PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT

________________________

No. 16-11818

________________________

D.C. Docket Nos. 1:14-cv-24061-JRG,

1:14-cv-24064-JRG

1:14-cv-24061-JRG

AMAL EGHNAYEM, 

MARGARITA M. DOTRES, 

MANIA NUNEZ, 

JUANA BETANCOURT, 

 Plaintiffs - Appellees,

MARGARETTE DUBOIS-JEAN,

 Plaintiff,

versus

BOSTON SCIENTIFIC CORPORATION, 

 Defendant -

Appellant.

_________________________________________________________

1:14-cv-24064-JRG Dismissed 02/23/2017

MARGARITA M. DOTRES,

 Plaintiff,

Case: 16-11818 Date Filed: 10/19/2017 Page: 1 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 2 of 43
2

versus

BOSTON SCIENTIFIC CORPORATION,

 Defendant.

_________________________________________________________

1:14-cv-24065-JRG

MANIA NUNEZ,

 Plaintiff - Appellee,

versus

BOSTON SCIENTIFIC CORPORATION,

 Defendant - Appellant.

_________________________________________________________

1:14-cv-24066-JRG

JUANA BETANCOURT,

 Plaintiff - Appellee,

versus

BOSTON SCIENTIFIC CORPORATION,

 Defendant - Appellant.

________________________

Appeal from the United States District Court

for the Southern District of Florida

________________________

(October 19, 2017)

Case: 16-11818 Date Filed: 10/19/2017 Page: 2 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 3 of 43
3

Before HULL, MARCUS, and ROGERS,

* Circuit Judges.

MARCUS, Circuit Judge: 

In this products liability suit, Boston Scientific Corporation 

(BSC) appeals from various orders and a final judgment in favor of the 

plaintiff, Amal Eghnayem. Eghnayem alleged substantial injuries 

caused by the Pinnacle Pelvic Floor Repair Kit, a transvaginal mesh 

prescription medical device manufactured and sold by BSC. She

initially filed suit in the Southern District of West Virginia as part of a 

transvaginal mesh Multidistrict Litigation; her suit was consolidated 

with three other similar suits and transferred to the Southern District of 

Florida for trial. The consolidated plaintiffs all brought the same four 

claims under Florida law, arguing that BSC was both negligent and 

strictly liable for the Pinnacle’s defective design, and both negligent 

and strictly liable for failing to warn them of the resultant danger from 

the Pinnacle. After eight days of trial, the jury found for each of the 

plaintiffs on all four claims, awarding more than six million dollars to 

each plaintiff. BSC now appeals from the judgment entered for

 * Honorable John M. Rogers, United States Circuit Judge for the Sixth Circuit, 

sitting by designation.

Case: 16-11818 Date Filed: 10/19/2017 Page: 3 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 4 of 43
4

Eghnayem.1

BSC argues that the district court abused its discretion in two 

distinct ways: by consolidating the four plaintiffs’ suits and trying them 

together, and by excluding all evidence relating to the Food and Drug 

Administration’s clearance of the Pinnacle for sale through its 510(k) 

“substantial equivalence” process. BSC also says that the district court 

erred in denying it judgment as a matter of law because Eghnayem 

failed to present sufficient evidence to prove her design defect claim; 

she failed to present sufficient evidence that the Pinnacle’s warnings 

were not per se adequate, and that the alleged failure to warn was the 

proximate cause of her injuries; and finally, the relevant statute of 

limitations barred all of her claims as a matter of law.

After thorough review, and having had the benefit of oral 

argument, we can discern no error in the district court’s rulings, and 

accordingly we affirm the judgment of the district court.

I.

The Pinnacle is a medical device used to remedy pelvic organ 

 1 BSC initially appealed from the judgment in favor of all four plaintiffs:

Eghnayem, Margarita M. Dotres, Mania Nuñez, and Juana Betancourt. Prior to oral 

argument, BSC dismissed the appeal as to Dotres. BSC has since moved to dismiss the 

appeal as to co-plaintiffs Nuñez and Betancourt as well. That motion is GRANTED.

Case: 16-11818 Date Filed: 10/19/2017 Page: 4 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 5 of 43
5

prolapse in a female patient. Essentially, this device is a mesh sheet 

that is implanted transvaginally and works by physically preventing

pelvic organs (the bladder, uterus, or rectum) from falling through the 

vagina. The mesh is made from polypropylene, a type of plastic. In 

2007, the FDA cleared BSC to sell the Pinnacle pursuant to its 510(k) 

process, which entailed finding that the Pinnacle was “substantially 

equivalent” to another device already available on the market. 

The plaintiff, Amal Eghnayem, had a Pinnacle surgically 

implanted on February 28, 2008, to treat her pelvic organ prolapse. In 

the months following her surgery, she began to experience bleeding and 

pain during intercourse, incontinence, and pelvic pain and pressure. 

She visited a doctor for these problems in October 2008, who 

performed a pelvic exam and told Eghnayem that she had exposed 

mesh in her vagina. The doctor performed in-office surgery to trim the 

exposed mesh in an attempt to alleviate Eghnayem’s symptoms. 

Unfortunately, this treatment did not resolve her problems, and in May 

2012, she visited another doctor and complained of similar symptoms. 

This doctor examined Eghnayem, found another mesh exposure, and 

performed a second mesh-removal surgery in August 2012. Since then, 

Case: 16-11818 Date Filed: 10/19/2017 Page: 5 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 6 of 43
6

Eghnayem’s pain has largely subsided, but she has lost vaginal 

sensitivity. 

Eghnayem and three other plaintiffs filed separate lawsuits 

against BSC in MDL 2326 -- In re: Boston Scientific Corporation 

Pelvic Repair System Products Liability Litigation -- in the United 

States District Court for the Southern District of West Virginia. They

each sought compensatory and punitive damages based on claims for 

negligent design defect, negligent failure to warn, strict-liability design 

defect, and strict-liability failure to warn. The district court sua sponte

consolidated the suits for all purposes, including trial. The court 

observed that, although “there will be separate evidence relating to 

failure to warn and individual damages,” “the similarities in these 

cases, particularly as to the claim of design defect,” outweighed the 

differences and warranted consolidation.

BSC moved the district court to sever the suits after discovery,

arguing that the similarities in the plaintiffs’ suits did not predominate 

and that consolidation would lead to jury confusion and prejudice. It

pointed out that each plaintiff had different complaints, different 

medical histories, and different treating doctors; was prescribed the 

Case: 16-11818 Date Filed: 10/19/2017 Page: 6 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 7 of 43
7

Pinnacle at different times for different conditions; and claimed to 

suffer different injuries, after different lengths of exposure, resulting in 

different treatment courses. But the district court was “unpersuaded 

that the barriers suggested by defendants in a consolidated trial [were]

insurmountable or [would] result in [ ] prejudice” and so denied BSC’s 

motion.

The consolidated case was transferred to the United States 

District Court for the Southern District of Florida. Prior to trial, the 

district court excluded all evidence relating to the Food and Drug 

Administration’s (“FDA”) regulatory scheme and clearance of the 

Pinnacle for sale pursuant to the 510(k) “substantial equivalence” 

process. The court excluded the evidence under both Federal Rule of 

Evidence 402, which provides that “[i]rrelevant evidence is not 

admissible,” and Federal Rule of Evidence 403, which provides that 

relevant evidence may be excluded “if its probative value is 

substantially outweighed by a danger of . . . unfair prejudice, confusing 

the issues, misleading the jury, undue delay, [or] wasting time.” 

Trial began in the Southern District of Florida on November 3, 

2014, and continued over eight days. The plaintiffs offered twenty-five 

Case: 16-11818 Date Filed: 10/19/2017 Page: 7 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 8 of 43
8

witnesses, including themselves and their implanting physicians. The 

witnesses, mostly doctors, testified regarding the plaintiffs’ medical 

conditions, implantation processes, and injuries; BSC’s structure and

policies; the Pinnacle’s development process; and the Pinnacle’s and 

polypropylene mesh’s chemical characteristics, design features, uses, 

and potential dangers. BSC contested all four of the plaintiffs’ claims 

on the merits and also asserted Florida’s four-year statute of limitations 

for products liability claims as an affirmative defense against 

Eghnayem’s claims in particular. At the conclusion of the plaintiffs’

case, and again after the conclusion of their own case, BSC moved for 

judgment as a matter of law on all claims; the district court deferred 

ruling. The jury returned a verdict in favor of each of the plaintiffs on 

all claims except for punitive damages, and rejected BSC’s statute of 

limitations defense, awarding $6,722,222 in damages to Eghnayem, 

$6,533,333 to Nuñez, $6,766,666 to Dotres, and $6,722,222 to 

Betancourt.

BSC renewed its motion for judgment as a matter of law on all of 

the plaintiffs’ claims. BSC argued, among other things, that Eghnayem 

failed to present sufficient evidence on her design defect claim; that the 

Case: 16-11818 Date Filed: 10/19/2017 Page: 8 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 9 of 43
9

Pinnacle’s warnings were adequate as a matter of law, and that 

regardless Eghnayem failed to show that the alleged failure to warn was 

the proximate cause of her injuries; and, finally, that the evidence 

indisputably showed that Eghnayem’s claims had accrued more than 

four years before she filed suit. The district court rejected all of these 

arguments, concluding that Eghnayem had provided sufficient evidence

to support her claims and thus they were all properly reserved for the 

jury.

BSC also moved in the alternative for a new trial on the grounds

that it was substantially prejudiced by the wrongful exclusion of the 

510(k) evidence, and that consolidation confused the jury and also 

prejudiced BSC. Again, the district court rejected these arguments,

based largely on the same reasoning it had provided in the initial 

consolidation and exclusion orders.

BSC now appeals the denial of these post-trial motions.

II.

We review a district court’s decision whether to consolidate 

multiple actions only for a “clear abuse of discretion.” Hendrix v. 

Raybestos-Manhattan, Inc., 776 F.2d 1492, 1495 (11th Cir. 1985). We 

Case: 16-11818 Date Filed: 10/19/2017 Page: 9 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 10 of 43
10

also review the evidentiary rulings of a trial court “only for a clear 

abuse of discretion.” United States v. Brannan, 562 F.3d 1300, 1306 

(11th Cir. 2009). “[W]e must affirm unless we find that the district 

court has made a clear error of judgment, or has applied the wrong 

legal standard.” Id. (quoting United States v. Frazier, 387 F.3d 1244, 

1259 (11th Cir. 2004) (en banc)). Finally, we review the district court’s 

ruling on a motion for judgment as a matter of law de novo, 

considering the evidence and the reasonable inferences drawn from it in 

the light most favorable to the nonmoving party. Middlebrooks v. 

Hillcrest Foods, Inc., 256 F.3d 1241, 1246 (11th Cir. 2001). Thus,

we’ve explained, “[j]udgment as a matter of law is appropriate only if 

the evidence is so overwhelmingly in favor of the moving party that a 

reasonable jury could not arrive at a contrary verdict.” Id.

III.

BSC first contends that the district court abused its discretion by

consolidating the plaintiffs’ suits, because individual issues 

predominated and the consolidation yielded unacceptable prejudice.

BSC also argues that the district court abused its discretion by 

excluding evidence relating to the Pinnacle’s clearance through the 

Case: 16-11818 Date Filed: 10/19/2017 Page: 10 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 11 of 43
11

FDA’s 510(k) regulatory process, because this evidence was relevant to 

the Pinnacle’s safety. Neither claim succeeds.

A.

The district court acted well within its discretion in consolidating 

each of these four lawsuits. Under Federal Rule of Civil Procedure

42(a), a district court may consolidate multiple actions that “involve a 

common question of law or fact.” A district court’s decision whether to 

consolidate is “purely discretionary.” Hendrix, 776 F.2d at 1495. In 

exercising its considerable discretion, the trial court is obliged to 

consider:

Whether the specific risks of prejudice and possible confusion are

overborne by the risk of inconsistent adjudications of common 

factual and legal issues, the burden on parties, witnesses and 

available judicial resources posed by multiple lawsuits, the length 

of time required to conclude multiple suits as against a single 

one, and the relative expense to all concerned of the single-trial, 

multiple-trial alternatives.

Id. (quotation omitted and alterations adopted). Moreover, “[t]he court 

must also bear in mind the extent to which the risks of prejudice and 

confusion that might attend a consolidated trial can be alleviated by 

utilizing cautionary instructions to the jury during the trial and 

controlling the manner in which the plaintiffs’ claims (including the 

Case: 16-11818 Date Filed: 10/19/2017 Page: 11 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 12 of 43
12

defenses thereto) are submitted to the jury for deliberation.” Id. “A 

joint trial is appropriate where there is clearly substantial overlap in the 

issues, facts, evidence, and witnesses required for claims against 

multiple defendants.” Allstate Ins. Co. v. Vizcay, 826 F.3d 1326, 1333 

(11th Cir. 2016) (quotation omitted and alteration adopted). But 

“[w]here prejudice to rights of the parties obviously results from the 

order of consolidation, the action of the trial judge has been held 

reversible error.” Dupont v. S. Pac. Co., 366 F.2d 193, 196 (5th Cir. 

1966).2 “District court judges in this circuit have been urged to make 

good use of Rule 42(a) in order to expedite the trial and eliminate 

unnecessary repetition and confusion.” Young v. City of Augusta, 59 

F.3d 1160, 1169 (11th Cir. 1995) (quotation omitted and alterations 

adopted).

The district court did not abuse its discretion in concluding that 

the considerations surrounding consolidation weighed in favor of 

joining these suits for trial. The plaintiffs all brought the same claims

based largely on the same facts: BSC’s Pinnacle device was 

 2 Former Fifth Circuit cases decided before October 1, 1981 are binding precedent 

in the Eleventh Circuit. See Bonner v. City of Prichard, 661 F.2d 1206, 1209 (11th 

Cir. 1981).

Case: 16-11818 Date Filed: 10/19/2017 Page: 12 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 13 of 43
13

unreasonably dangerous by design, and BSC failed to include sufficient 

warnings with the device to alert physicians to that danger. Although

each plaintiff’s proof of causation was necessarily different, generally 

differences in causation are not enough, standing alone, to bar 

consolidation of products liability claims. And any danger of prejudice 

arising from the consolidation was reduced in this case, because the 

district court explained the consolidated nature of the trial to the jury

and expressly instructed it to consider each plaintiff’s claims 

separately. Notably, this is not the first time we have affirmed the 

consolidation of products liability claims that require individual 

evidence of causation. Thus, for example, in Hendrix v. RaybestosManhattan, Inc., we affirmed a district court’s decision to consolidate 

four products liability cases that all alleged that asbestos exposure 

caused them to contract an asbestos-related disease, notwithstanding 

the presentation of different bodies of proof on causation. 776 F.2d at 

1495–96.

BSC nonetheless contends that consolidation was improper 

because the plaintiffs’ evidence was presented in a confusing and 

disjointed manner, but this argument is largely beside the point. 

Case: 16-11818 Date Filed: 10/19/2017 Page: 13 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 14 of 43
14

Confusing or not, most of the evidence went toward the common 

claims among the plaintiffs: (1) whether the Pinnacle was a defective 

medical device and (2) whether the Pinnacle’s warnings were 

sufficient. The only evidence that went to the individual claims came 

from the more-easily-distinguishable doctors who did each plaintiff’s 

implantation, and concerned comparatively straightforward questions: 

(1) did the Pinnacle’s design cause that plaintiff’s injuries, and (2) did 

the lack of sufficient warnings influence that doctor’s decision to 

implant the Pinnacle. BSC has not shown that this individual evidence 

made the suit so confusing that it was obviously prejudiced and thus 

has failed to tie the confusion to the consolidation order.

BSC also suggests that the plaintiffs’ similar damages awards in 

the amounts of $6,766,666, $6,722,222, $6,722,222, and $6,533,333,

respectively, show that the jury was confused by the consolidated suits. 

The district court rejected this argument too because BSC failed to 

point to any direct source of the jury’s alleged confusion, and instead 

effectively “work[ed] backwards, speculating as to the reason for the 

compensatory awards based on the end result.” The district court was 

correct. Nearly identical or identical damages awards, without more, 

Case: 16-11818 Date Filed: 10/19/2017 Page: 14 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 15 of 43
15

simply are not sufficient evidence of juror confusion. The plaintiffs 

suffered similar injuries caused by the same product, and so might 

reasonably be due similar relief. And notably, the awards were not all 

identical; the fact that two were the same and two were different 

strongly suggests that the jury considered each plaintiff individually. 

BSC fails to point us to any evidence that the jury’s decision to award 

similar damages to each plaintiff was improper. This allegation of 

confusion is far from enough to show that the district court abused its 

discretion.

BSC also says that consolidating the four plaintiffs for trial led 

the jury to believe that their claims were more likely to be true, but this 

argument fails. For starters, the district court instructed the jury that 

“[y]ou may not even consider the fact that there’s more than one case 

being brought,” an instruction that the jury presumably followed. See

United States v. Stone, 9 F.3d 934, 938 (11th Cir. 1993) (“Few tenets 

are more fundamental to our jury trial system than the presumption that 

juries obey the court’s instructions.”). And even had the cases not been 

consolidated, the plaintiffs would likely have been able to submit 

evidence of other patients with similar injuries to show the dangerous 

Case: 16-11818 Date Filed: 10/19/2017 Page: 15 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 16 of 43
16

character of the Pinnacle. See, e.g., Jones v. Otis Elevator Co., 861 

F.2d 655, 661 (11th Cir. 1988) (“We have held that evidence of similar 

accidents might be relevant to the defendant’s notice, magnitude of the 

danger involved, the defendant’s ability to correct a known defect, the 

lack of safety for intended uses, strength of a product, the standard of 

care, and causation.”) (quotation omitted). Moreover, consolidation of 

products liability cases will always implicate this concern, and this 

Court has affirmed consolidation in these kinds of cases before. See, 

e.g., Hendrix, 776 F.2d at 1495–96.

BSC’s final argument is that, due to the differences in the 

plaintiffs’ claims, consolidation allowed evidence into trial that would 

have been individually inadmissible for some of the plaintiffs. This 

claim fails as well. As an initial matter, BSC failed to request limiting 

instructions for any of the challenged evidence. The failure to 

contemporaneously raise the issue denied the district court the chance 

to address the problem by issuing limiting instructions, and it deprives 

this Court of the benefit of the district court’s decisions. See Access 

Now, Inc. v. Sw. Airlines Co., 385 F.3d 1324, 1331 (11th Cir. 2004) 

(“[A]s a court of appeals, we review claims of judicial error in the trial 

Case: 16-11818 Date Filed: 10/19/2017 Page: 16 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 17 of 43
17

courts. If we were to regularly address questions -- particularly factbound issues -- that [the district court] never had a chance to examine, 

we would not only waste our resources, but also deviate from the 

essential nature, purpose, and competence of an appellate court.”); see 

also Fisher v. Ciba Specialty Chems. Corp., 245 F.R.D. 539, 543 n.7 

(S.D. Ala. 2007) (noting that “appropriate limiting instructions” can be 

used to cabin “evidence relevant to the claims of one plaintiff but not to 

others”); United States v. Miranda, 197 F.3d 1357, 1360 (11th Cir. 

1999) (“The failure to give a limiting instruction is error only when 

such an instruction is requested.”). BSC’s failure severely weakens its

argument.

Moreover, it’s far from clear that the complained-of evidence 

would have been excludable even if each of the plaintiffs had tried their 

cases alone. BSC identifies three pieces of evidence that may have 

been inadmissible in individual trials: graphic images and testimony 

regarding one plaintiff’s removed mesh; information about another

plaintiff’s future scheduled surgery; and evidence relating to BSC’s 

practices and the Pinnacle’s safety that post-dated some but not all of 

the plaintiffs’ implantations. As for the first, BSC generally objected to 

Case: 16-11818 Date Filed: 10/19/2017 Page: 17 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 18 of 43
18

the graphic images and testimony under Rule 403, arguing that the 

possibility of prejudice substantially outweighed any probative value. 

The court overruled that objection, and that decision was not an abuse 

of discretion. Graphic medical photos and testimony, while potentially 

disturbing, might also be particularly helpful in allowing a jury to better 

understand a medical device and the allegedly related injuries. See

Aycock v. R.J. Reynolds Tobacco Co., 769 F.3d 1063, 1069 (11th Cir. 

2014) (“[A] district court’s discretion to exclude evidence under Rule 

403 is narrowly circumscribed.”) (quotation omitted); Gen. Elec. Co. v. 

Joiner, 522 U.S. 136, 141 (1997) (“[A]buse of discretion is the proper 

standard of review of a district court’s evidentiary rulings.”). In this 

case, the very feature that made the images graphic -- the tissue that 

was removed along with the mesh -- is what made them relevant to the 

plaintiffs’ claim that the very nature of the Pinnacle’s design prevented

the removal of the mesh without removing tissue. BSC has not 

convinced us that this evidence would have been any less relevant, or 

any more prejudicial, in individual trials. See Hahn v. Sterling Drug, 

Inc., 805 F.2d 1480, 1483 (11th Cir. 1986) (noting that evidence of 

prior incidents that might be relevant to “the magnitude of danger,” 

Case: 16-11818 Date Filed: 10/19/2017 Page: 18 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 19 of 43
19

“the lack of safety,” or “causation” “should not be excluded”).

As for the second challenged piece of evidence, BSC did not 

object at all to the two mentions of one plaintiff’s future scheduled 

surgery, and further has not suggested that this evidence would be 

excludable in individual trials under any rule of evidence except 

perhaps Rule 403. We fail to see how the danger of unfair prejudice 

from the mere mention of future surgery warrants invoking the strong 

medicine of Rule 403 exclusion. See United States v. Dodds, 347 F.3d 

893, 897 (11th Cir. 2003) (“[W]e have [ ] recognized that Rule 403 is 

an extraordinary remedy which the district court should invoke 

sparingly, and the balance should be struck in favor of admissibility.”) 

(quotation omitted and alteration adopted). Once again, BSC has not

shown that this evidence would have been inadmissible for some of the 

plaintiffs individually.

Finally, as for the third challenged set of evidence, BSC fails to 

show that the evidence post-dating some of the 

implantations -- including admissions from BSC employees tending to 

show a pattern of insufficient research for other medical devices, and 

information suggesting a high erosion rate for the Pinnacle -- would not 

Case: 16-11818 Date Filed: 10/19/2017 Page: 19 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 20 of 43
20

be admissible for at least some purposes in each individual trial. A 

pattern of insufficient research might be probative evidence as to 

whether BSC designs products without due care, and the Pinnacle’s 

high erosion rate is surely probative of whether BSC was strictly liable 

for a defective product. BSC is of course correct that this evidence 

could not have been used to show BSC’s knowledge of the risks 

associated with the Pinnacle for those plaintiffs whose implantations 

predated the evidence. But when evidence is relevant for some 

purposes and not others, limiting instructions -- not exclusion -- are 

generally the best way to handle the issue. See, e.g., Fisher, 245 F.R.D. 

at 543 n.7. BSC’s failure to request limiting instructions here dooms 

this argument.

Quite simply, BSC cannot establish that it was prejudiced by the 

consolidation of the plaintiffs’ suits. The district court did not abuse its 

discretion in ordering the consolidation and denying BSC a new trial.

B.

The district court also did not abuse its discretion when it 

excluded BSC’s 510(k) evidence. The 510(k) review process 

originates from the Medical Device Amendments of 1976 (MDA) to 

Case: 16-11818 Date Filed: 10/19/2017 Page: 20 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 21 of 43
21

the Federal Food, Drug, and Cosmetic Act. The MDA was enacted in 

order to “impose[ ] a regime of detailed federal oversight” of medical 

devices. Riegel v. Medtronic, Inc., 552 U.S. 312, 316 (2008). Under 

the MDA, certain devices must complete a thorough premarket 

approval (PMA) process with the FDA before they may be marketed, 

including all devices that cannot “provide reasonable assurance of 

the[ir] safety and effectiveness” under less stringent scrutiny, and that 

are “purported or represented to be for a use in supporting or sustaining 

human life or for a use which is of substantial importance in preventing 

impairment of human health” or “present[ ] a potential unreasonable 

risk of illness or injury.” Id. at 317; 21 U.S.C. § 360c(a)(1)(C). The 

PMA process requires the applicant to demonstrate a “reasonable 

assurance” that the device is both “safe . . . [and] effective under the 

conditions of use prescribed, recommended, or suggested in the 

proposed labeling thereof.” Buckman Co. v. Plaintiffs’ Legal Comm., 

531 U.S. 341, 344 (2001); 21 U.S.C. § 360e(d)(2)(A), (B).

An exemption to the PMA requirement exists for medical devices 

that were already on the market prior to the MDA’s enactment in 1976; 

these devices are allowed to remain on the market until the FDA 

Case: 16-11818 Date Filed: 10/19/2017 Page: 21 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 22 of 43
22

initiates and completes PMA review for them. See 21 U.S.C. 

§ 360e(b)(1)(A); Buckman, 531 U.S. at 345. In order to ameliorate the 

monopolistic consequences of this exemption, the MDA also allows

other manufacturers to market devices that are shown to be 

“substantially equivalent” to pre-1976 devices that are exempt from the 

PMA requirement. Buckman, 531 U.S. at 345 (citing § 360e(b)(1)(B)). 

The 510(k) process is the method by which a manufacturer 

demonstrates substantial equivalence. Id.

Notably, the PMA and 510(k) processes have distinct 

requirements and different goals. PMA “is federal safety review,” 

Riegel, 552 U.S. at 323, whereas “the 510(k) process is focused on 

equivalence, not safety,” Medtronic, Inc. v. Lohr, 518 U.S. 470, 493 

(1996) (quotation omitted and alteration adopted). Indeed, “devices 

that enter the market through § 510(k) have never been formally 

reviewed . . . for safety or efficacy.” Riegel, 552 U.S. at 323 (quotation 

omitted). Rather, the 510(k) exemption is “intended merely to give 

manufacturers the freedom to compete, to a limited degree, with and on 

the same terms as manufacturers of medical devices that existed prior 

to 1976.” Lohr, 518 U.S. at 494. 

Case: 16-11818 Date Filed: 10/19/2017 Page: 22 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 23 of 43
23

These differences are reflected in the intensity of review: “[I]n 

contrast to the 1,200 hours necessary to complete a PMA review, the 

§ 510(k) review is completed in an average of only 20 hours.” Id. at 

479; see also Goodlin v. Medtronic, Inc., 167 F.3d 1367, 1369 n.1 

(11th Cir. 1999) (“[T]he FDA completes the average 510k review 

within 20 hours, and the agency considers only whether the device is 

indeed the equivalent of a preexisting device -- regardless of how 

unsafe or ineffective the grandfathered device happens to be.”). The 

two processes are “by no means comparable.” Lohr, 518 U.S. at 478.

Based on the arguments properly presented in this appeal,3 it is 

clear that the district court did not abuse its discretion when it 

concluded that the 510(k) review process is not relevant to a product’s 

safety. As the district court explained, “[i]f 510(k) does not go to a 

product’s safety and efficacy -- the very subjects of the plaintiffs’ 

 3 In its reply brief, BSC argues for the first time that because the FDA determined 

the Pinnacle to be substantially equivalent to a post-1976 Class II device that may have 

undergone formal safety review, as opposed to a pre-1976 Class III device which had

not, BSC’s 510(k) evidence could be relevant to the Pinnacle’s safety in a way that 

distinguishes this case from Lohr and Riegel. Because BSC failed to raise this 

argument in the district court, or even on appeal prior to its reply brief, we will not

consider it. See Access Now, Inc., 385 F.3d at 1331 (explaining that “an issue not 

raised in the district court . . . will not be considered by this [C]ourt”) (quotation 

omitted); Lovett v. Ray, 327 F.3d 1181, 1183 (concluding that an argument raised for 

the first time in a reply brief is not properly before this Court).

Case: 16-11818 Date Filed: 10/19/2017 Page: 23 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 24 of 43
24

products liability claims -- then evidence of BSC’s compliance with 

510(k) has no relevance to the state law claims in this case.” This 

evidence was properly excluded under Rule 402.

BSC’s arguments to the contrary do not undermine this 

conclusion. BSC claims that the evidence is relevant because the 

plaintiffs based much of their case on the theory that BSC didn’t 

perform sufficient safety testing, and because Florida has established a 

rebuttable presumption that a product is not defective if it complies 

with applicable safety regulations. But these points simply beg the 

question; because 510(k) is not a safety regulation, approval under that 

process cannot show that BSC performed sufficient testing or complied 

with applicable safety regulations. BSC also argues that the district 

court’s conclusion misapplied Lohr and Riegel because those cases 

dealt with 510(k)’s relevance to safety in the context of preemption of 

state-law claims, not evidence admissibility. But the district court 

simply applied the Supreme Court’s reasoning from those cases to 

reach a related, though technically distinct, conclusion -- a basic and 

entirely proper form of judicial analysis.

But even if the 510(k) evidence were relevant, the district court 

Case: 16-11818 Date Filed: 10/19/2017 Page: 24 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 25 of 43
25

still did not abuse its discretion when it excluded it under Rule 403. As 

the district court noted, the evidence “might have provoked the parties 

to engage in a time-consuming mini-trial on whether BSC in fact 

complied with [FDA] regulations.” And the apparent significance of 

federal regulatory schemes very well might have misled the jury into 

thinking that general federal regulatory compliance, not state tort 

liability, was the core issue. These concerns of prejudice and confusion 

substantially outweighed the probative value of the evidence, 

which -- divorced as it was from any clear showing of safety review for 

the Pinnacle or a substantially similar device -- was low at best. 

Although BSC argues that any possibility of prejudice could have been

“resolved with an appropriate instruction” to the jury, that option does 

not come close to tipping the scale in their favor. Weighing all these 

considerations, the court acted within its discretion by excluding the 

510(k) evidence.

We are not the only circuit court to have approved exclusion of 

510(k) evidence under Rule 403. The Fourth Circuit, in In re C.R. 

Bard, Inc., MDL No. 2187, Pelvic Repair System Products Liability 

Litigation, 810 F.3d 913 (4th Cir. 2016) -- reviewing another order 

Case: 16-11818 Date Filed: 10/19/2017 Page: 25 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 26 of 43
26

excluding 510(k) evidence for a vaginal mesh device -- explained that, 

even “[a]ssuming without deciding that the 510(k) compliance 

evidence is relevant,” the evidence had diminished probative value 

because 510(k) “operate[s] to exempt devices from rigorous safety 

review procedures.” Id. at 920. The court held that the district court 

did not abuse its discretion when it concluded that the possibility of 

“mini-trials” on the 510(k) process -- which would have included a 

“battle of experts” -- presented “the very substantial dangers of 

misleading the jury and confusing the issues.” Id. at 921–22 (quotation 

omitted). The Fourth Circuit explained the issue this way:

While 510(k) clearance might, at least tangentially, say 

something about the safety of the cleared product, it does not say 

very much that is specific. The vast majority of courts have said 

so, and having been thoroughly briefed not only by the parties but 

by several amici, we say so again today. As such, the district 

court did not abuse its discretion when it determined that 

allowing the 510(k) evidence in on the question of design defect 

would be substantially more prejudicial than probative.

Id. at 922.

IV.

Even setting aside the issues of consolidation and exclusion of 

the 510(k) evidence, BSC argues that the district court should have 

Case: 16-11818 Date Filed: 10/19/2017 Page: 26 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 27 of 43
27

granted it judgment as a matter of law on Eghnayem’s design defect 

and failure to warn claims, because she didn’t present enough evidence 

to establish debatable questions of fact and because her claims were 

untimely. After thoroughly reviewing this record, we are satisfied that 

Eghnayem provided sufficient evidence in her favor, so her claims were 

properly reserved for the jury. The district court did not err by 

declining to overturn the jury’s verdict.

A.

The district court did not err by denying judgment as a matter of 

law to BSC on Eghnayem’s design defect claims. We are Erie-bound 

in diversity cases to apply the tort law of Florida. Erie R. Co. v. 

Tompkins, 304 U.S. 64, 78 (1938). In Florida, “a product is defectively 

designed if the plaintiff proves that the design of the product 

proximately caused the plaintiff’s injuries and the defendant fails to 

prove that on balance, the benefits of the design outweigh the risk of 

danger inherent in the design.” Force v. Ford Motor Co., 879 So. 2d 

103, 106 (Fla. Dist. Ct. App. 2004). This test, known as the “riskutility” test, is one of two ways to show that a design is defective under 

the strict products liability standard laid out in the Second Restatement 

Case: 16-11818 Date Filed: 10/19/2017 Page: 27 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 28 of 43
28

of Torts. Jennings v. BIC Corp., 181 F.3d 1250, 1255 (11th Cir. 1999). 

We have acknowledged that Florida has adopted this standard. Id.

(citing West v. Caterpillar Tractor Co., 336 So. 2d 80, 87 (Fla. 1976)). 

In this case, the jury was instructed on only the risk-utility test.

Eghnayem presented expert testimony of two specific defects in 

the Pinnacle: the polypropylene material may experience oxidative 

degradation, which causes it to lose its physical and mechanical 

properties in a way that causes injury; and the crosshatched design of 

the mesh makes it very difficult, if not impossible, to remove if there is 

a problem with the mesh.

Regarding polypropylene degradation, Eghnayem presented 

expert testimony from Dr. Mays (qualified as an expert in the field of 

polymer science) that polypropylene reacts with oxygen, and “[w]hen 

that oxidative process progresses enough, the material erodes away.” 

When this happens, the polypropylene “stiffen[s]” and “lose[s] [its]

mechanical properties,” which “is relevant to the proper or improper 

use of polypropylene in a medical device.” Mays further explained that 

“if you increase the surface area of the material, . . . [y]ou’re going to 

increase the rate at which that material undergoes degradation,” and 

Case: 16-11818 Date Filed: 10/19/2017 Page: 28 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 29 of 43
29

that for polypropylene fibers -- a category that the Pinnacle falls 

into -- “physical properties deteriorate more rapidly upon oxidation.” 

Finally, Mays noted that degradation occurs in the body “much more 

readily than it does in many other environments,” and once it occurs the 

material “can no longer move with the body.” Mays testified that there 

is evidence that polypropylene degrades “when implanted in the female 

pelvis,” and that such degradation may result in stiffness and ultimately 

“a sawing effect” that Mays believed “caus[ed] some of the problems 

with the mesh.” Another expert, Dr. Walmsley (qualified as an expert 

in the field of urology), testified that when treating pelvic organ 

prolapse with polypropylene mesh, there are “mesh-specific risks” of 

pelvic pain, erosion, painful activity, and permanent tissue damage, 

along with a significant risk of subsequent surgery as compared to other 

prolapse surgical repairs -- approximately a “threefold” increase. 

As for the difficulty surrounding the removal of the 

polypropylene mesh, Dr. Margolis (qualified as an expert in the fields

of obstetrics and gynecology) opined that the implantation of the mesh, 

which has a “crosshatched” or “window screen[ ]” pattern of holes, was 

“irreversible” because “[s]car tissue, what are called fibroblasts, scar 

Case: 16-11818 Date Filed: 10/19/2017 Page: 29 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 30 of 43
30

cells, move into the [holes in the] mesh and they cement the mesh into 

place.” Margolis explained that this aspect of the mesh implantation 

makes it very difficult to treat mesh injuries, complications, and 

erosions. 

When taken in concert, this expert testimony provided a 

sufficient foundation for a reasonable jury to conclude that the design 

of the mesh increased both the potential for degradation and the 

difficulty of removal. The ultimate question whether these risks 

outweighed the Pinnacle’s benefits was for a jury to decide. The 

district court correctly did not second-guess the jury’s verdict.

BSC’s arguments to the contrary are unavailing. BSC claims that 

the “purported design defect is a matter not of kind (like the presence of 

polypropylene) but of degree (the surface area of polypropylene),” and 

thus that Eghnayem was required to establish “the minimum threshold 

beyond which the product is defective.” But this argument is a red 

herring. This type of analysis is used in toxic tort cases, where some 

exposure to a toxic substance may be acceptable, but past a certain 

threshold exposure becomes harmful. See, e.g., McClain v. Metabolife 

Int’l, Inc., 401 F.3d 1233, 1241 (11th Cir. 2005) (“In toxic tort cases, 

Case: 16-11818 Date Filed: 10/19/2017 Page: 30 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 31 of 43
31

scientific knowledge of the harmful level of exposure to a chemical 

plus knowledge that plaintiff was exposed to such quantities are 

minimal facts necessary to sustain the plaintiff’s burden.”) (quotation 

omitted and alteration adopted). But in this case, there is no question of 

threshold; the Pinnacle was either harmful or not.

BSC also argues that Eghnayem’s implanting physician testified 

that polypropylene was safe and effective, and that this somehow 

defeats her claim of a design defect. But any testimony from her 

experts that tended to weaken her design defect claim is irrelevant to 

judgment as a matter of law; the weighing of conflicting evidence is 

properly for the jury. See Pensacola Motor Sales Inc. v. E. Shore 

Toyota, LLC, 684 F.3d 1211, 1226 (11th Cir. 2012) (explaining that, in 

reviewing the denial of a motion for judgment as a matter of law, “we 

must disregard all evidence favorable to the moving party that the jury 

is not required to believe”) (quotation omitted).

Taking the evidence in the light most favorable to Eghnayem, 

there was sufficient evidence for a reasonable jury to find that the 

Pinnacle had a design defect. Accordingly, the district court correctly

denied BSC’s motion for judgment as a matter of law.

Case: 16-11818 Date Filed: 10/19/2017 Page: 31 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 32 of 43
32

B.

The district court did not err by denying judgment as a matter of 

law to BSC on Eghnayem’s failure to warn claims either. Under 

Florida law, to succeed on a failure to warn claim a plaintiff must show 

(1) that the product warning was inadequate; (2) that the inadequacy 

proximately caused her injury; and (3) that she in fact suffered an 

injury from using the product. Hoffmann-La Roche Inc. v. Mason, 27 

So. 3d 75, 77 (Fla. Dist. Ct. App. 2009). For medical products like the 

Pinnacle, “the duty to warn is directed to physicians rather than patients 

under the ‘learned intermediary’ doctrine.” Id. This is so because the 

prescribing physician acts as an intermediary between the manufacturer 

and the consumer, weighing the potential benefits of a device against 

the dangers in deciding whether to recommend it to meet the patient’s 

needs. Felix v. Hoffmann-LaRoche, Inc., 540 So. 2d 102, 104 (Fla. 

1989). Consequently, to satisfy the causation element, a plaintiff must 

show that her treating physician would not have used the product had 

adequate warnings been provided. See id. at 105 (explaining that “the 

drug manufacturer could not be penalized for the failure of the doctor 

to impart knowledge concerning the dangers of the drug of which the 

Case: 16-11818 Date Filed: 10/19/2017 Page: 32 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 33 of 43
33

doctor had been warned and was aware”).

“While in many instances the adequacy of warnings . . . is a 

question of fact,” the Florida Supreme Court has held that “it can 

become a question of law where the warning is accurate, clear, and 

unambiguous.” Felix, 540 So. 2d at 105. “[T]he adequacy or 

inadequacy of the warning to inform a physician must, except in the 

more obvious situations, be proved by expert testimony.” Upjohn Co. 

v. MacMurdo, 562 So. 2d 680, 683 (Fla. 1990). “To warn adequately, 

the [warning] label must make apparent the potential harmful 

consequences.” Farias v. Mr. Heater, Inc., 684 F.3d 1231, 1233 (11th 

Cir. 2012) (quoting Scheman-Gonzalez v. Saber Mfg. Co., 816 So. 2d 

1133, 1139 (Fla. Dist. Ct. App. 2002)). Generally, “[t]he warning must 

be of such intensity as to cause a reasonable man to exercise for his 

own safety caution commensurate with the potential danger.” Id.

(quoting Scheman-Gonzalez, 816 So. 2d at 1139). But “[w]hen a 

warning is designed to inform a ‘learned intermediary,’ it is somewhat 

easier to establish the adequacy of the warning because it will be read 

and considered by a trained expert.” Hayes v. Spartan Chem. Co., 622 

So. 2d 1352, 1354 (Fla. Dist. Ct. App. 1993).

Case: 16-11818 Date Filed: 10/19/2017 Page: 33 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 34 of 43
34

The Florida Supreme Court has ruled at least twice in notable

cases that warnings were adequate as a matter of law. In Felix, the 

court considered a label warning that explained “[b]ecause 

teratogenicity has been observed in animals given [the drug], patients 

who are pregnant or intend to become pregnant” should not use it, and 

female patients “should be fully counseled on the potential risks to the 

fetus should they become pregnant while undergoing treatment.” Felix, 

540 So. 2d at 103. The court noted that the prescribing doctor testified 

that he understood the warnings, and ultimately ruled that these 

warnings were adequate as a matter of law to alert physicians to the 

possible risk of birth defects from the drug. Id. at 105. In Upjohn, the 

Florida Supreme Court considered a warning that mentioned the 

following potential adverse reactions: breakthrough bleeding, spotting, 

and change in menstrual flow. Upjohn, 562 So. 2d at 682. The court 

observed that “no medical expert testified that the package insert was 

insufficient to put a doctor on notice” that the medication could cause 

the plaintiff’s “excessive and continuous menstrual bleeding,” and 

concluded that, as “the insert warned of the possibility of abnormal 

bleeding outside of the menstrual period,” “[i]t would be unreasonable 

Case: 16-11818 Date Filed: 10/19/2017 Page: 34 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 35 of 43
35

to hold Upjohn liable for not characterizing the bleeding as excessive, 

continuous, or prolonged.” Id. at 683.

At trial Eghnayem argued that BSC failed to warn doctors that, in 

the event of a problem with the Pinnacle, it could be difficult or even 

impossible to remove. The Pinnacle’s directions for use contained the 

following warnings:

Hysterectomy may be needed in the future; Use of mesh may 

make future hysterectomies more difficult due to tissue in-growth 

and scarring.

In the event that infection presents post procedure, the entire 

mesh many have to be removed or revised.

Tissue responses to the implant could include local irritation at 

the wound site, vaginal erosion or exposure through the urethra 

or other surrounding tissue, migration of the device from the 

desired location, fistula formation, foreign body reaction, and 

inflammation. The occurrence of these responses may require 

removal or revision of the mesh.

Eghnayem offered expert testimony from Dr. Margolis that these 

warnings failed to inform doctors that “a patient may need multiple 

operative procedures to remove the mesh”; that “when you remove 

portions of the mesh, part of the normal tissue has to come out with it,” 

so that “you can[not] just take the mesh out and everything is fine”; and 

that mesh implantation ultimately may be “irreversible.”

Case: 16-11818 Date Filed: 10/19/2017 Page: 35 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 36 of 43
36

Eghnayem carried her burden here. While the Pinnacle’s 

warnings may have been sufficient to notify doctors that multiple 

procedures might be needed to remove the mesh, the warnings do not 

even remotely suggest that removal might be impossible. Indeed, the 

repeated warnings that removal might be necessary suggest just the 

opposite. And the warnings also failed to notify doctors that removal 

of the mesh might require removal of healthy tissue as well. The 

closest they come is by warning that “future hysterectomies [may be] 

more difficult due to tissue in-growth and scarring,” but that warning is 

not so unambiguous that it would be unreasonable for a jury to hold 

BSC liable for failure to warn.

BSC argues, nevertheless, that the Pinnacle’s warnings were 

sufficiently clear that they merited judgment as a matter of law under 

Upjohn. But the district court was correct to conclude that “the 

difference between Upjohn and the case at bar is one of degree -- the 

injuries experienced by the plaintiff in Upjohn were a minor departure 

from the risks warned of in the package insert, but the same cannot be 

said here.” Because the Pinnacle warnings did not explain that the 

complications they warned of could be “permanent, irreversible, and 

Case: 16-11818 Date Filed: 10/19/2017 Page: 36 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 37 of 43
37

untreatable,” the departure was not so minor that the entry of judgment 

as a matter of law was warranted. 

Eghnayem also proffered sufficient evidence that BSC’s failure 

to warn caused her injuries. BSC argues that she failed to show that the 

inadequate warnings affected her doctor’s decision to use the Pinnacle, 

but her doctor testified that he would have liked to know the risk of 

mesh contracture, acute and permanent inflammation, and chronic pain, 

and that had he known he would have had “concerns about [ ] using 

[the Pinnacle] in a patient” and would have discussed those concerns 

with Eghnayem. This testimony does not “point so overwhelmingly in 

favor of” BSC that no reasonable jury could find that the failure to 

warn proximately caused Eghnayem’s injuries. Slicker v. Jackson, 215 

F.3d 1225, 1229 (11th Cir. 2000) (quotation omitted).

C.

Finally, the district court did not err by denying judgment as a 

matter of law to BSC on its argument that Eghnayem’s claims were 

time barred. It was not unreasonable for the jury to find that 

Eghnayem’s claims accrued after April 11, 2009 -- the cut-off point for 

the state’s four-year statute of limitations.

Case: 16-11818 Date Filed: 10/19/2017 Page: 37 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 38 of 43
38

Under Florida law, plaintiffs have four years to bring a products

liability action. Fla. Stat. §§ 95.11(3)(e), 95.031. Accrual for these 

actions is governed by the discovery rule, according to which the 

statute of limitations period does not begin to run until “the date that 

the facts giving rise to the cause of action were discovered, or should 

have been discovered with the exercise of due diligence.” Id. § 

95.031(2)(b). The Florida Supreme Court has explained that the 

knowledge required to commence the running of the limitations period 

under the discovery rule need “not rise to that of legal certainty.” Univ. 

of Miami v. Bogorff, 583 So. 2d 1000, 1004 (Fla. 1991), holding 

modified on other grounds by Tanner v. Hartog, 618 So. 2d 177 (Fla. 

1993). Rather, “[p]laintiffs need only have notice, through the exercise 

of reasonable diligence, of the possible invasion of their legal rights.” 

Id. Notice, in turn, “ha[s] two essential ingredients: an injury distinct in 

some way from conditions naturally to be expected from the plaintiff’s 

condition, and . . . exposure to the product in question.” Babush v. Am. 

Home Prods. Corp., 589 So. 2d 1379, 1381 (Fla. Dist. Ct. App. 1991)

(emphasis omitted). “Use of the conjunction ‘and’ in this equation 

necessarily implies that the connection must be to some extent causal.”

Case: 16-11818 Date Filed: 10/19/2017 Page: 38 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 39 of 43
39

Id.

Florida precedent sheds considerable light on what it takes for an 

injury to meet this notice standard. In Bogorff, the Florida Supreme 

Court concluded that a three-year-old’s symptoms of slurred speech, 

impaired motor skills, convulsions, coma, and resultant paralysis and 

brain damage, which coincided in time with the introduction of a 

particular leukemia medication, were sufficiently dramatic to provide 

notice to his parents. 583 So. 2d at 1001, 1004. In Norsworthy v. 

Holmes Reg’l Med. Ctr., Inc., on the other hand, a Florida appellate 

court held -- in the highly analogous medical malpractice context -- that 

a child’s difficulty breathing following an invasive medical procedure 

was not so obviously unusual that it put his parents on notice of their 

malpractice claim. 598 So. 2d 105, 108 (Fla. Dist. Ct. App. 1992). The 

court explained that when “there is nothing about an injury that would 

communicate to a reasonable lay person that the injury is more likely a 

result of some failure of medical care than a natural occurrence that can 

arise in the absence of medical negligence, the knowledge of the injury 

itself does not necessarily trigger the running of the statute of 

limitations.” Id. at 107. Because even “medical treatment competently 

Case: 16-11818 Date Filed: 10/19/2017 Page: 39 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 40 of 43
40

performed” might cause new unpleasant symptoms, an injury must 

stand out from the norm to start the statutory clock. Id. at 108.

Thus, to merit judgment as a matter of law for BSC, the evidence 

must have been clear that Eghnayem was aware of a “dramatic change 

in [her] condition,” and further that she knew of the possible 

involvement of the Pinnacle in that change, by April 11, 2009 -- four 

years before she filed suit. See Bogorff, 583 So. 2d at 1004; 

Middlebrooks, 256 F.3d at 1246. The evidence was not that clear.

While Eghnayem did exhibit one new symptom in 2008 -- urinary 

incontinence -- that could have been associated with a defect in the 

Pinnacle, that symptom was not so obviously unusual as to indisputably 

put Eghnayem on notice about her claim. Incontinence is a more 

dramatic symptom than some, but judgment as a matter of law is a high 

standard, and it was not “patently clear” or “obvious” that Eghnayem’s 

incontinence was a sufficiently distinct symptom from what might be 

expected after vaginal surgery to put her on notice of her cause of 

action against BSC. See United States v. Groessel, 440 F.2d 602, 606 

(5th Cir. 1971).

BSC argues that Eghnayem’s testimony that, after consulting 

Case: 16-11818 Date Filed: 10/19/2017 Page: 40 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 41 of 43
41

with her doctor in October 2008, she believed this new symptom 

“w[as] related to the mesh repair” showed she was on notice at that 

time. But “mesh repair” could refer to the implantation surgery, along 

with any complications, as opposed to the Pinnacle device itself.

BSC’s protestation to the contrary -- that “[n]o rational juror could 

conclude that Eghnayem testified the implant surgery, rather than the 

mesh itself, was ‘related’ to her ‘problems’” because “[s]he never 

blamed her surgeon, and she presented no evidence that her ‘problems’ 

were caused by surgical technique” -- misses the point. The question is 

not whether a reasonable jury could conclude that her injuries were 

caused by the surgery, but rather whether the jury could conclude that 

Eghnayem reasonably believed that her incontinence was a result of the 

surgery instead of the Pinnacle. Ultimately, a jury could have 

reasonably concluded that Eghnayem’s injury was not so “distinct . . .

from conditions naturally to be expected from [her post-surgical] 

condition,” and so the timeliness of Eghnayem’s action was properly a 

question of fact for the jury. Babush, 589 So. 2d at 1381.

The long and short of it is that the district court properly 

Case: 16-11818 Date Filed: 10/19/2017 Page: 41 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 42 of 43
42

exercised its broad discretion in consolidating these actions and 

refusing to admit FDA evidence, and the contested fact questions were 

properly presented to the jury.

AFFIRMED.

Case: 16-11818 Date Filed: 10/19/2017 Page: 42 of 42 

Case 2:15-md-02641-DGC Document 8384-1 Filed 10/24/17 Page 43 of 43